|
1
|
Vanpouille-Box C, Pilones KA, Wennerberg
E, Formenti SC and Demaria S: In situ vaccination by radiotherapy
to improve responses to anti-CTLA-4 treatment. Vaccine.
33:7415–7422. 2015. View Article : Google Scholar
|
|
2
|
Song CW, Glatstein E, Marks LB, Emami B,
Grimm J, Sperduto PW, Kim MS, Hui S, Dusenbery KE and Cho LC:
Biological principles of stereotactic body radiation therapy (SBRT)
and stereotactic radiation surgery (SRS): Indirect cell death. Int
J Radiat Oncol Biol Phys. 110:21–34. 2021. View Article : Google Scholar
|
|
3
|
Postow MA, Callahan MK, Barker CA, Yamada
Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al:
Immunologic correlates of the abscopal effect in a patient with
melanoma. N Engl J Med. 366:925–931. 2012. View Article : Google Scholar
|
|
4
|
Formenti SC, Rudqvist NP, Golden E, Cooper
B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari
de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces
responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851.
2018. View Article : Google Scholar
|
|
5
|
Podder TK, Fredman ET and Ellis RJ:
Advances in radiotherapy for prostate cancer treatment. Adv Exp Med
Biol. 1096:31–47. 2018. View Article : Google Scholar
|
|
6
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar
|
|
7
|
Nesslinger NJ, Sahota RA, Stone B, Johnson
K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, et
al: Standard treatments induce antigen-specific immune responses in
prostate cancer. Clin Cancer Res. 13:1493–1502. 2007. View Article : Google Scholar
|
|
8
|
Lockney NA, Zhang M, Morris CG, Nichols
RC, Okunieff P, Swarts S, Zhang Z, Zhang B, Zhang A and Hoppe BS:
Radiation-induced tumor immunity in patients with non-small cell
lung cancer. Thorac Cancer. 10:1605–1611. 2019. View Article : Google Scholar
|
|
9
|
Schaue D, Comin-Anduix B, Ribas A, Zhang
L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K and McBride
WH: T-cell responses to survivin in cancer patients undergoing
radiation therapy. Clin Cancer Res. 14:4883–4890. 2008. View Article : Google Scholar
|
|
10
|
Takeshima T, Chamoto K, Wakita D, Ohkuri
T, Togashi Y, Shirato H, Kitamura H and Nishimura T: Local
radiation therapy inhibits tumor growth through the generation of
tumor-specific CTL: Its potentiation by combination with Th1 cell
therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar
|
|
11
|
Glanville J, Huang H, Nau A, Hatton O,
Wagar LE, Rubelt F, Ji X, Han A, Krams SM, Pettus C, et al:
Identifying specificity groups in the T cell receptor repertoire.
Nature. 547:94–98. 2017. View Article : Google Scholar
|
|
12
|
Meysman P, De Neuter N, Gielis S, Bui Thi
D, Ogunjimi B and Laukens K: On the viability of unsupervised
T-cell receptor sequence clustering for epitope preference.
Bioinformatics. 35:1461–1468. 2019. View Article : Google Scholar
|
|
13
|
Larkin MA, Blackshields G, Brown NP,
Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm
A, Lopez R, et al: Clustal W and Clustal X version 2.0.
Bioinformatics. 23:2947–2948. 2007. View Article : Google Scholar
|
|
14
|
Cavanaugh SX, Fuller CD, Kupelian PA,
Reddy C, Bradshaw P, Pollock BH and Fuss M: Time and PSA threshold
model prognosticates long-term overall and disease-specific
survival in prostate cancer patients as early as 3 months after
external beam radiation therapy. Prostate Cancer Prostatic Dis.
8:353–358. 2005. View Article : Google Scholar
|
|
15
|
Link B, Torres Crigna A, Holzel M,
Giordano FA and Golubnitschaja O: Abscopal effects in metastatic
cancer: Is a predictive approach possible to improve individual
outcomes? J Clin Med. 10:51242021. View Article : Google Scholar
|
|
16
|
Dong N, Moreno-Manuel A, Calabuig-Farinas
S, Gallach S, Zhang F, Blasco A, Aparisi F, Meri-Abad M, Guijarro
R, Sirera R, et al: Characterization of circulating T cell receptor
repertoire provides information about clinical outcome after PD-1
blockade in advanced non-small cell lung cancer patients. Cancers
(Basel). 13:29502021. View Article : Google Scholar
|
|
17
|
Liu S, Pan W, Cheng Z, Sun G, Zhu P, Chan
F, Hu Y, Zhang X and Dai Y: Characterization of the T-cell receptor
repertoire by deep T cell receptor sequencing in tissues from
patients with prostate cancer. Oncol Lett. 15:1744–1752. 2018.
|
|
18
|
Baxevanis CN, Fortis SP and Perez SA:
Prostate cancer: Any room left for immunotherapies? Immunotherapy.
11:69–74. 2019. View Article : Google Scholar
|
|
19
|
De Velasco MA and Uemura H: Prostate
cancer immunotherapy: Where are we and where are we going? Curr
Opin Urol. 28:15–24. 2018. View Article : Google Scholar
|
|
20
|
Ryan MJ and Bose R: Genomic alteration
burden in advanced prostate cancer and therapeutic implications.
Front Oncol. 9:12872019. View Article : Google Scholar
|
|
21
|
Fraser M, Sabelnykova VY, Yamaguchi TN,
Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X,
Masella AP, et al: Genomic hallmarks of localized, non-indolent
prostate cancer. Nature. 541:359–364. 2017. View Article : Google Scholar
|
|
22
|
Wang L, Pan S, Zhu B, Yu Z and Wang W:
Comprehensive analysis of tumour mutational burden and its clinical
significance in prostate cancer. BMC Urol. 21:292021. View Article : Google Scholar
|
|
23
|
Reiser JB, Darnault C, Gregoire C, Mosser
T, Mazza G, Kearney A, van der Merwe PA, Fontecilla-Camps JC,
Housset D and Malissen B: CDR3 loop flexibility contributes to the
degeneracy of TCR recognition. Nat Immunol. 4:241–247. 2003.
View Article : Google Scholar
|
|
24
|
Birnbaum ME, Mendoza JL, Sethi DK, Dong S,
Glanville J, Dobbins J, Ozkan E, Davis MM, Wucherpfennig KW and
Garcia KC: Deconstructing the peptide-MHC specificity of T cell
recognition. Cell. 157:1073–1087. 2014. View Article : Google Scholar
|
|
25
|
Yu K, Shi J, Lu D and Yang Q: Comparative
analysis of CDR3 regions in paired human αβ CD8 T cells. FEBS Open
Bio. 9:1450–1459. 2019. View Article : Google Scholar
|
|
26
|
Stadinski BD, Shekhar K, Gomez-Tourino I,
Jung J, Sasaki K, Sewell AK, Peakman M, Chakraborty AK and Huseby
ES: Hydrophobic CDR3 residues promote the development of
self-reactive T cells. Nat Immunol. 17:946–955. 2016. View Article : Google Scholar
|
|
27
|
Reuben A, Gittelman R, Gao J, Zhang J,
Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, et al: TCR
repertoire intra- tumor heterogeneity in localized lung
adenocarcinomas: An association with predicted neoantigen
heterogeneity and postsurgical recurrence. Cancer Discov.
7:1088–1097. 2017. View Article : Google Scholar
|
|
28
|
Dovedi SJ, Cheadle EJ, Popple AL, Poon E,
Morrow M, Stewar t R, Yusko EC, Sanders CM, Vignali M, Emerson RO,
et al: Fractionated radiation therapy stimulates antitumor immunity
mediated by both resident and infiltrating polyclonal T-cell
populations when combined with PD-1 blockade. Clin Cancer Res.
23:5514–5526. 2017. View Article : Google Scholar
|
|
29
|
Valpione S, Mundra PA, Galvani E, Campana
LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N
and Marais R: The T cell receptor repertoire of tumor infiltrating
T cells is predictive and prognostic for cancer survival. Nat
Commun. 12:40982021. View Article : Google Scholar
|
|
30
|
Wu L, Zhu J, Rudqvist NP, Welsh J, Lee P,
Liao Z, Xu T, Jiang M, Zhu X, Pan X, et al: T-cell receptor
profiling and prognosis after stereotactic body radiation therapy
for stage I non-small-cell lung cancer. Front Immunol.
12:7192852021. View Article : Google Scholar
|
|
31
|
Di Virgilio F: Liaisons dangereuses:
P2X(7) and the inflammasome. Trends Pharmacol Sci. 28:465–472.
2007. View Article : Google Scholar
|
|
32
|
Martinon F, Mayor A and Tschopp J: The
inflammasomes: Guardians of the body. Annu Rev Immunol. 27:229–265.
2009. View Article : Google Scholar
|
|
33
|
Sun L, Wu J, Du F, Chen X and Chen ZJ:
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates
the type I interferon pathway. Science. 339:786–791. 2013.
View Article : Google Scholar
|
|
34
|
Ablasser A, Goldeck M, Cavlar T, Deimling
T, Witte G, Röhl I, Hopfner KP, Ludwig J and Hornung V: cGAS
produces a 2′-5′-linked cyclic dinucleotide second messenger that
activates STING. Nature. 498:380–384. 2013. View Article : Google Scholar
|
|
35
|
Ishikawa H, Ma Z and Barber GN: STING
regulates intracellular DNA-mediated, type I interferon-dependent
innate immunity. Nature. 461:788–792. 2009. View Article : Google Scholar
|
|
36
|
Deng L, Liang H, Xu M, Yang X, Burnette B,
Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al:
STING-dependent cytosolic DNA sensing promotes radiation-induced
type I inter- feron-dependent antitumor immunity in immunogenic
tumors. Immunity. 41:843–852. 2014. View Article : Google Scholar
|
|
37
|
Burnette BC, Liang H, Lee Y, Chlewicki L,
Khodarev NN, Weichselbaum RR, Fu YX and Auh SL: The efficacy of
radio- therapy relies upon induction of type i interferon-dependent
innate and adaptive immunity. Cancer Res. 71:2488–2496. 2011.
View Article : Google Scholar
|
|
38
|
Rodriguez-Ruiz ME, Vanpouille-Box C,
Melero I, Formenti SC and Demaria S: Immunological mechanisms
responsible for radiation-induced abscopal effect. Trends Immunol.
39:644–655. 2018. View Article : Google Scholar
|
|
39
|
Matsumura S, Wang B, Kawashima N,
Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti
SC, Dustin ML and Demaria S: Radiation-induced CXCL16 release by
breast cancer cells attracts effector T cells. J Immunol.
181:3099–3107. 2008. View Article : Google Scholar
|
|
40
|
Lim JY, Gerber SA, Murphy SP and Lord EM:
Type I interferons induced by radiation therapy mediate recruitment
and effector function of CD8(+) T cells. Cancer Immunol Immunother.
63:259–271. 2014. View Article : Google Scholar
|
|
41
|
Matsumura S and Demaria S: Up-regulation
of the pro-inflammatory chemokine CXCL16 is a common response of
tumor cells to ionizing radiation. Radiat Res. 173:418–425. 2010.
View Article : Google Scholar
|
|
42
|
Chow J, Hoffend NC, Abrams SI, Schwaab T,
Singh AK and Muhitch JB: Radiation induces dynamic changes to the T
cell repertoire in renal cell carcinoma patients. Proc Natl Acad
Sci USA. 117:23721–23729. 2020. View Article : Google Scholar
|
|
43
|
Vanpouille-Box C, Alard A, Aryankalayil
MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN,
Formenti SC and Demaria S: DNA exonuclease Trex1 regulates
radiotherapy-induced tumour immunogenicity. Nat Commun.
8:156182017. View Article : Google Scholar
|
